Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines for preventing malaria.

P Graves1, H Gelband

  • 1Dept of Preventive Medicine & Biometrics, University of Colorado Health Sciences Center, Box C 245, 4200 E Ninth Ave, Denver, CO 80262, USA. Patricia.Graves@uchsc.edu

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Part I. the Global Antibiotic Resistance Partnership (GARP).

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2011
Same author

Part V. Surveillance activities.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2011
Same author

Part VII. Interventions.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2011
Same author

WITHDRAWN: Vaccines for preventing malaria.

The Cochrane database of systematic reviews·2007
Same author

WITHDRAWN: Vaccines for preventing anthrax.

The Cochrane database of systematic reviews·2007
Same author

Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis.

The Cochrane database of systematic reviews·2007
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Malaria vaccines SPf66 showed no protection against P. falciparum in Africa but a modest reduction in other regions. NANP vaccines provided no evidence of protection. Further research may be warranted for SPf66 in South America.

Area of Science:

  • Immunology
  • Tropical Medicine
  • Vaccinology

Background:

  • Malaria remains a significant global health challenge, particularly in sub-Saharan Africa, necessitating novel control strategies.
  • Existing malaria vaccines, including SPf66 (asexual stages) and NANP (sporozoite stages), have undergone randomized clinical trials.

Purpose of the Study:

  • To systematically evaluate the efficacy of malaria vaccines through a comprehensive review of randomized clinical trials.
  • To assess the protective effects of SPf66 and NANP vaccines against Plasmodium falciparum and Plasmodium vivax malaria.

Main Methods:

  • Searched multiple databases (Cochrane, Medline, Embase) and contacted experts for relevant randomized trials.
  • Included trials comparing malaria vaccines (SPf66, NANP) against placebo for Plasmodium species.

Related Experiment Videos

  • Two independent reviewers assessed trial quality and extracted data.

    • Main Results:

    • Thirteen trials with ~7700 participants were analyzed. SPf66 showed no efficacy against P. falciparum in African children under 5.
    • SPf66 demonstrated a modest reduction in P. falciparum malaria incidence in trials outside Africa (OR 0.77, 95% CI 0.67-0.88).
    • SPf66 had no significant effect on P. vivax malaria incidence, and NANP vaccines showed no protective effect against P. falciparum.

    Conclusions:

    • SPf66 vaccines do not provide protection against P. falciparum malaria in Africa, but offer modest benefits in other regions.
    • Further investigation of SPf66 vaccines in South America may be justified.
    • Current trials are insufficient to assess vaccine impact on malaria mortality or severe disease; NANP vaccine efficacy remains unevaluated.